The innovative prescription medication sotorasib, marketed under the Lumakras name, was developed by Amgen. Adult patients with non-small cell lung cancer (NSCLC) who have a particular mutation called KRAS G12C are treated with it. Lumakras, the first targeted medicine created especially for this genetic mutation, was approved by the U.S. Food and Drug Administration (FDA) in May 2021, giving patients who had few other treatment options fresh hope.

What is Sotorasib 120 mg (Lumakras)?

A KRAS G12C inhibitor called sotorasib is intended to stop the aberrant signaling cascade brought on by this particular genetic mutation. The KRAS gene controls cell survival and division and is essential for cell signaling. Cancer can result from a mutation that causes cells to expand out of control, especially at the G12C location. In order to successfully cut off the cancer-causing signal and delay or stop tumor growth, sotorasib targets and binds to the mutant KRAS protein in its dormant state.

Lumakras is usually used orally once a day and contains 120 mg of sotorasib per tablet. At the recommended dosage of 960 mg (8 tablets) once daily, the yellow, film-coated tablets come in bottles with 240 pills, for a 30-day supply.

Indications and Usage

Sotorasib, also known as Lumakras, is prescribed to treat:

KRAS G12C mutations in adults with locally progressed or metastatic non-small cell lung cancer (NSCLC)

Individuals with at least one history of systemic treatment, such as immunotherapy or chemotherapy

Before beginning treatment, the KRAS G12C mutation must be verified with an FDA-approved test.

Mechanism of Action

The KRAS G12C mutant protein is locked in its inactive GDP-bound state when sotorasib binds to its cysteine residue irreversibly. This stops the downstream signaling via the MAPK/ERK pathway, which is in charge of encouraging the survival and growth of cancer cells. Lumakras aids in halting the development of cancer cells fueled by the KRAS G12C mutation by blocking this pathway.

Administration & Dosage

The suggested dosage is 960 mg taken orally once daily (8 120 mg pills).

It is recommended that tablets be consumed whole rather than broken, chewed, or divided.

Suitable for use with or without food

Skip the dose and take the next one that is scheduled if a dose is missed by more than six hours.

Side Effects of Lumakras (Sotorasib)

Like all medications, Sotorasib may cause side effects. The most common include:

Diarrhea

Nausea

Fatigue

Hepatotoxicity (elevated liver enzymes)

Cough

Arthralgia (joint pain)

Liver function tests (LFTs) should be monitored regularly during treatment due to the risk of hepatotoxicity. In some cases, dosage modification or discontinuation may be necessary.

Precautions and Warnings

Sotorasib 120 mg (Lumakras) Prior to and during therapy, keep an eye on liver enzyme levels. Elevated ALT/AST values may require dose modifications or cessation.

Drug Interactions: Acid-reducing agents, P-gp, and CYP3A4-affecting medications may interact with sotorasib.

GI Problems: Exercise caution while treating patients who have a history of GI problems. Report any ongoing diarrhea or stomach pain right away.

Reproductive Toxicity: Little is known about how it affects fetal development and fertility. During treatment and for a week following the last dose, women who are capable of having children should utilize an effective form of birth control.

Clinical Efficacy

In patients with NSCLC who had previously received treatment, sotorasib demonstrated a positive overall response rate (ORR) of 36% in the CodeBreaK 100 clinical trial, with a median duration of response of 10 months. Sotorasib is a promising therapy choice for this challenging cancer subtype, as seen by the data, which showed significant clinical benefit.

Keeping and Managing

Lumakras tablets should be kept between 20°C and 25°C (68°F and 77°F) at room temperature.

To shield the bottle from light and moisture, keep it tightly closed.

Keep out of children’s reach.

Conclusion

An important turning point in customized cancer treatment has been reached with sotorasib 120 mg (Lumakras). Patients with advanced non-small cell lung cancer (NSCLC) who had few other therapy options now have a customized option thanks to its specialized targeting of the KRAS G12C mutation. Being the first of its kind, sotorasib continues to open the door for further advancements in targeted cancer therapy while also setting a new benchmark in precision oncology.

Consult your oncologist about Lumakras’ potential as a therapeutic option if you or a loved one has non-small cell lung cancer (NSCLC) with the KRAS G12C mutation.

Order Now At Mdx Pharma bd….

To order from MDX Pharma BD, visit their website at https://mdxpharmabd.com, where you can browse products and place orders online. For inquiries or orders via email, contact emedicarepharma@gmail.com. Alternatively, call (+88) 01929123476. Their address is 29, Abdullahpur, Uttara, Dhaka-1230, Bangladesh.

What is the purpose of sotorasib (Lumakras)?
Adults with non-small cell lung cancer (NSCLC) who have a KRAS G12C mutation and whose disease has advanced following at least one previous systemic therapy are treated with sotorasib.

1. How does Sotorasib work?
Sotorasib is a KRAS G12C inhibitor. It helps prevent the growth and division of cancer cells by blocking the KRAS G12C protein.

2. What is the typical Sotorasib dosage?
Eight 120 mg pills taken at once, with or without food, constitute the usual dose of 960 mg once daily.

3. Is it possible to eat 120 mg pills of sotorasib with food?
Yes, you can take sotorasib with or without food. It should, however, be taken daily at the same time.

4. Can Sotorasib be used in combination with other therapies?
Currently, Sotorasib is used as a single agent, not in combination. To assess combination medicines, clinical trials are still being conducted.

5. Does starting Sotorasib need genetic testing?
Patients must have an FDA-approved test that confirms a KRAS G12C mutation before starting treatment.